It’s easy to get sticker shock when considering the price of a new drug. But lawmakers would be wise to consider the value that new drugs like Cobenfy can deliver for patients, their families and the healthcare system at large today—and in the years to come.
Late last month, the U.S. Food and Drug Administration approved Bristol Myers Squibb’s KarXT, a treatment for schizophrenia. The drug, which will be marketed under the brand name Cobenfy, is promising not just because it is effective at treating the debilitating mental health condition. It also seems not to have the potentially harmful side effects that have characterized previous schizophrenia treatments.
The drug’s journey from the lab through regulatory approval is a case study in how America’s world-class scientists work to bring groundbreaking cures to patients. At a time when many progressive lawmakers are actively working to disrupt this system—and see the pharmaceutical industry as a piggy bank for funding all manner of government spending—Cobenfy serves as a reminder for what works, and why our market-oriented system is worth preserving.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.
New Schizophrenia Drug Represents Promise Of Pharmaceutical Innovation
Sally C. Pipes
It’s easy to get sticker shock when considering the price of a new drug. But lawmakers would be wise to consider the value that new drugs like Cobenfy can deliver for patients, their families and the healthcare system at large today—and in the years to come.
Late last month, the U.S. Food and Drug Administration approved Bristol Myers Squibb’s KarXT, a treatment for schizophrenia. The drug, which will be marketed under the brand name Cobenfy, is promising not just because it is effective at treating the debilitating mental health condition. It also seems not to have the potentially harmful side effects that have characterized previous schizophrenia treatments.
The drug’s journey from the lab through regulatory approval is a case study in how America’s world-class scientists work to bring groundbreaking cures to patients. At a time when many progressive lawmakers are actively working to disrupt this system—and see the pharmaceutical industry as a piggy bank for funding all manner of government spending—Cobenfy serves as a reminder for what works, and why our market-oriented system is worth preserving.
Read the entire op-ed in Forbes.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.